Systemic Lupus Erythematosus Clinical Trials

14 trials recruiting in Canada.

Arthritis & Autoimmune

Recruiting Drug Device Behavioral Older adults Healthy volunteers

11 trials

Testing Enpatoran against a placebo for systematic lupus erythematosus

Explore this study →

There are 2 groups in this study. Group A receives Enpatoran, together with one or more of: Standard of care (SoC). Group B, the placebo group, receives Placebo, together with one or more of: Standard of care (SoC).

One site, in Kelowna

Phase 3
2 groups
One site, in Kelowna
Recruiting

Official title: A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Systematic Lupus Erythematosus · EMD Serono Research & Development Institute, Inc.

Testing Obinutuzumab against a placebo for lupus nephritis

Explore this study →

There are 3 groups in this study. Groups A and C receive Obinutuzumab, together with one or more of: Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone and Prednisone. Group B, the placebo group, receives Placebo, together with one or more of: Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone and Prednisone.

Sites in Montreal and Toronto

Phase 2
3 groups
Sites in Toronto and Montreal
Recruiting

Official title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Lupus Nephritis · Hoffmann-La Roche

Comparing 3 approaches for systemic lupus erythematosus (with and without nephritis)

Explore this study →

There are 3 groups in this study. Group A receives ALLO-329 and Cyclophosphamide. Group B receives ALLO-329. Group C receives ALLO-329, Cyclophosphamide and Fludarabine.

One site, in Montreal

Phase 1
3 groups
One site, in Montreal
Recruiting

Official title: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic Lupus Erythematosus (With and Without Nephritis) · Allogene Therapeutics

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for systemic lupus erythematosus.

Testing DZP against a placebo for systemic lupus erythematosus

Explore this study →

There are 2 groups in this study. Group A receives DZP. Group B, the placebo group, receives Placebo.

Sites in Québec, Rimouski and 1 more city

Phase 3
2 groups
Sites in Québec, Rimouski and 1 more city
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus · UCB Biopharma SRL

Testing Anifrolumab with Anifrolumab for systemic sclerosis cutaneous lupus e myopathies systemic

Explore this study →

Everyone in this study is in one group and receives Anifrolumab.

One site, in Québec

Phase 3
1 group
One site, in Québec
Recruiting

Official title: Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus · AstraZeneca

Testing AZD5492 for systemic lupus erythematosus

Explore this study →

There are 2 groups in this study. Groups A and B receive AZD5492.

Sites in Hamilton and Sherbrooke

Phase 1
2 groups
Sites in Hamilton and Sherbrooke
Recruiting

Official title: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Systemic Lupus Erythematosus · AstraZeneca

Testing Ianalumab against a placebo for systemic lupus erythematosus

Explore this study →

There are 3 groups in this study. Groups A and B receive Ianalumab. Group C, the placebo group, receives Placebo.

Sites in Rimouski, Toronto and 1 more city

Phase 3
3 groups
Sites in Vancouver, Toronto and 1 more city
Recruiting

Official title: Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Systemic Lupus Erythematosus · Novartis Pharmaceuticals

Testing Anifrolumab against a placebo for systemic lupus erythematosus

Explore this study →

There are 2 groups in this study. Group A receives Anifrolumab. Group B, the placebo group, receives Placebo.

Sites in Calgary, Toronto and 1 more city

Phase 3
2 groups
Sites in Calgary, Vancouver and 1 more city
Recruiting

Official title: An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Systemic Lupus Erythematosus · AstraZeneca

Testing Anifrolumab for systemic lupus erythematosus

Explore this study →

Everyone in this study is in one group and receives Anifrolumab.

Sites in Calgary, Hamilton and 3 more cities

Phase 3
1 group
Sites in Calgary, Richmond and 3 more cities
Recruiting

Official title: A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Systemic Lupus Erythematosus · AstraZeneca

Testing AZD0120 with Cyclophosphamide for systemic lupus erythematosus

Explore this study →

Everyone in this study receives AZD0120, together with one or more of: Cyclophosphamide and Fludarabine.

One site, in Toronto

Phase 1
1 group
One site, in Toronto
Recruiting

Official title: A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Lupus Erythematosus, Systemic · AstraZeneca

Comparing Application without occlusion in Area 1 with Application without occlusion in Area 2 for discoid lupus erythematosus

Explore this study →

There are 2 groups in this study. Group A receives Ruxolitinib 1.5% cream, together with one or more of: Application without occlusion in Area 1 and Application under occlusion at night in Area 2. Group B receives Ruxolitinib 1.5% cream, together with one or more of: Application under occlusion at night in Area 1 and Application without occlusion in Area 2.

Sites in Fredericton and Montreal

Phase 2
2 groups
Sites in Fredericton and Montreal
Recruiting

Official title: Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

Discoid Lupus Erythematosus · Innovaderm Research Inc.

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Systemic Lupus Erythematosus trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.